Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.

Pharmacogenomics - 1 Jan 2015

Parham Laura R, Briley Linda P, King Karen S, Byrne Julie, Rappold Erica, Goss Paul E, Spraggs Colin F

Abstract excerpt

Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash. 1191 participants from a large lapatinib monotherapy trial underwent HLA genotyping, and allele carriage frequencies between rash cases and controls were compared. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA
Share to Drug Eruptions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Heterozygote

Share to HLA Antigens

Share to Lapatinib

Share to Quinazolines

Source

Identifiers

PMID: 26265235
DOI: 10.2217/pgs.15.69

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.PMID 26265235Read ↗

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Semantic proximity Read ↗

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.Semantic proximity Read ↗

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.Semantic proximity Read ↗

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.Semantic proximity Read ↗

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.Semantic proximity Read ↗

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.Semantic proximity Read ↗

HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors.Semantic proximity Read ↗

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.